Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • Feb 28, 2011

166_ip_2011-02-28_07eb5f5b-fc73-46e0-91fb-e2978f32f9c5.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Analyst Meeting – 2010 Results

February 23, 2011

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

2010 – An Outstanding Year for Fresenius

    • Record sales and earnings – guidance / mid-term targets fully met or exceeded
  • -Double-digit earnings growth in all business segments
  • -Significant IV drug growth in North America
  • -Share conversion and change of legal form

Fresenius Group: Financial Results

5-year CAGR: 10%

EBIT5-year CAGR: 14%

Net Income5-year CAGR: 19%

Group financial results before APP-transaction-related special items

Fresenius Group: 15/15 Mid-term Goal Exceeded

Fresenius Group: Financial Results by Business Segment

F
Y
2
0
1
0		 F
i
r
e
s
e
n
u
s
M
d
i
l
C
e
c
a
a
r
e		 F
i
r
e
s
e
n
u
s
K
b
i
a		 F
i
r
e
s
e
n
u
s
H
l
i
e
o
s		 F
i
r
e
s
e
n
u
s
V
d
a
m
e
l
S
a
e
s
h
G
t
r
o
w		 \$
S
2
0
3
U
1
5
m
,
7
%		 €
3
6
7
2
m
,
1
9
%		 €
2
5
2
0
m
,
4
%		 €
7
1
3
m
1
5
%
E
B
I
T
h
G
t
r
o
w		 \$
S
9
2
U
1
4
m
,
0
1
%		 €
7
3
7
m
2
1
%		 €
2
3
5
m
1
5
%		 €
4
1
m
1
4
%

Fresenius Group: Distribution of Sales and Group Net Income

Fresenius Medical Care Fresenius excluding Fresenius Medical Care

1Net income attributable to Fresenius SE & Co. KGaA and before special items due to MEB and CVR accounting

€Fresenius SE & Co. KGaA: 18th Consecutive Dividend Increase Proposed

Fresenius Kabi: Achievements 2010

  • Outstanding organic sales growth of 12%, strong 20.1% EBIT margin
  • 29% sales growth at APP Pharmaceuticals driven by
  • new product launches (2010: 7 APP, 3 Kabi Oncology approvals, e.g. Oxaliplatin, Aztreonam, Topotecan)
  • drug shortage related sales, in particular Propofol
  • APP acquisition is clearly accretive to 2010 Group EPS

Fresenius Kabi: An Attractive Emerging Market and Patent-Cliff Play

S
i
i
f
i
g
n
c		 i
t
a
n
e
m
e
r
g
n
g		 k
t
m
a
r
e
p
o		 t
s
u
r
e
F
K
t
o
n
n
c
u
r
y
r
a		 k
i
S
l
n
g
e
a
s		 3
l
C
G
A
R
o
g
e
-y
r
r
s
a
s		 f
l
#
o
e
m
p
o
e
e
y
s		 l
t
p
n
a
s
C
h
i
n		 3
#
a
:		 €
3
0
3
m		 %
1
7		 3
6
0
0
~
,		 4
B
r
a
z		 i
l
#
5
:		 €
8
1
5
m		 6
%
1		 0
0
1
4
~
,		 2

Patent-cliff drives injectable generic growth

  • -US: >US\$22 bn in branded sales1 will go off-patent by 2020
  • -28 ANDAs pending plus ~40 products in development at APP
  • -Additional growth momentum outside the US

1Based on 2009 revenues

Fresenius Helios: Achievements 2010

  • 5% organic sales growth
  • patient admissions +4%
  • price/mix +1%
  • Record 9.3% EBIT margin (+80 bps)
  • Continued quality improvement: 85% of quality targets met or exceeded (2009: 82%)
  • 267-bed Helmstedt hospital (Lower Saxony) acquired Maximum-care hospitals

Fresenius Vamed: Achievements 2010

  • Excellent year with 15% sales and 14% EBIT growth – exceeding guidance
  • Project business sales +16% Service business sales +14%
  • Order entry (€625 million) and order backlog (€801 million) at or near all-time high
  • Major Q4/10 orders turnkey hospital project in Gabon (€76 million), rehab center in Austria (€22 million)

Fresenius Group: Where are we Heading Mid term?

Additional growth through small / mid-sized acquisitions

Focus on quality and cost leadership

Mid-term stretch financial goal: Group net income >€1 bn by 2014

Group Financials 2010 Outlook 2011

Fresenius Group: 2010 Guidance Fully Achieved or Exceeded

G
i
d
2
0
0
1
u
a
n
c
e		 l
R
t
e
s
u		 2
0
1
0
h
R
t
e
e
n
e
g
o
v
u
r
w
t
t
t
a
c
o
n
s
a
n
c
e
n
c
u
r
r
y		 8
9
%
–		 8
%
1
h
N
i
t
t
e
n
c
o
m
e
g
o
r
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 2
0
%
~		 2
3
%
C
a
p
e
x		 f
l
5
%
G
o
r
o
u
p
s
a
e
s
~		 5
%

1 Net income attributable to Fresenius SE & Co. KGaA and before special items due to MEB and CVR accounting

Fresenius Business Segments: 2010 Guidance Fully Achieved or Exceeded

G
i
d
2
0
1
0
a
n
c
e
u		 R
l
t
2
0
1
0
e
s
u
i
F
r
e
s
e
n
u
s
K
b
i
a		 l
h
S
t
a
e
s
g
o
r
w
E
B
I
T
i
m
a
r
g
n		 1
2
%
i
o
g
a
n
c
r
~
2
0
%
~		 1
2
%
i
o
g
a
n
c
r
2
0
%
1
F
i
r
e
s
e
n
u
s
l
i
H
e
o
s		 S
l
h
t
a
e
s
g
r
o
w
E
B
I
T		 3
%
i
5
o
r
g
a
n
c
–
€
2
3
0
2
3
5
m
–		 %
i
5
o
r
g
a
n
c
€
2
3
5
m
F
i
r
e
s
e
n
s
u
V
d
a
m
e		 S
l
h
t
a
e
s
g
r
o
w
h
E
B
I
T
t
g
o
r
w		 0
%
1
>
1
0
%
>		 %
1
5
1
4
%
F
i
r
e
s
e
n
s
u
B
i
h
t
o
e
c		 E
B
I
T		 €
3
0
5
4
m
-
–
-		 €
3
2
m
-

"_" verbal guidance → upper end; Fresenius Biotech →lower end

Fresenius Group: Profit and Loss Statement

€
m		 /
Q
4
1
0		 /
F
Y
1
0		 G
/
h
F
Y
1
0
Y
Y
t
r
o
w
o
l
t
a
c
u
a
t
r
a
e
s		 t
t
c
o
n
s
a
n
t
r
a
e
s
l
S
a
e
s		 4
1
5
1
,		 1
5
9
7
2
,		 1
3
%		 8
%
E
B
I
T		 6
2
4		 2
8
4
1
,		 8
%
1		 3
%
1
N
i
t
t
t
e
n
e
e
s
r		 1
4
2
-		 5
6
6
-		 2
%		 6
%
I
t
n
c
o
m
e
a
x
e
s		 3
1
7
-		 0
9
6
-		 3
2
%
-		 2
6
%
-
1
i
N
t
e
n
c
o
m
e		 6
1
5		 6
6
0		 2
8
%		 2
3
%

1 Net income attributable to Fresenius SE & Co. KGaA and before special items due to MEB and CVR accounting

Fresenius Kabi: EBIT Fully in Line with Upgraded Guidance

€
m		 /
Q
4
1
0		 2
0
1
0		 2
0
0
9		 G
h
t
r
o
w
E
o
p
e
u
r
M
i
a
g
n
r		 9
0
2
0.
5
%		 3
5
9
2
1.
1
%		 3
3
5
2
1.
4
%		 7
%
h
N
A
i
t
o
m
e
a
r
r
c
M
i
a
g
n
r		 9
3
3
8.
0
%		 3
3
5
3
4
4
%		 2
6
1
2
9
7
%		 %
5
5
/
/
f
A
P
L
A
M
A
i
r
c
a
i
M
a
r
g
n		 4
9
8.
%
1
4		 1
8
3
8.
%
1
4		 1
5
1
9
%
1
1		 2
1
%
/
C
&
t
R
D
o
p
o
a
e
r
r		 2
5
-		 0
1
4
-		 9
5
-		 %
4
7
-
T
l
E
B
I
T
t
o
a		 8
1
0		 7
3
7		 6
0
7		 %
2
1
M
i
a
r
g
n		 1
9
0
%		 2
0
1
%		 1
9
7
%

Fresenius Helios:

Sales and EBIT Growth Fully in Line with Upgraded Guidance

€
m		 2
0
1
0		 2
0
0
9		 G
h
t
r
o
w
T
l
l
t
o
a
s
a
e
s		 2
5
2
0
,		 2
4
1
6
,		 %
4
E
B
I
T
f
b
l
h
d
l
l
E
i
i
i
i
t
t
s
a
s
e
c
n
c
p
o
o
o
r
M
i
a
r
g
n		 2
3
5
9
3
%		 1
2
0
6
8.
6
%		 1
4
%
/
A
i
i
i
D
i
i
t
t
t
c
q
s
o
n
s
e
s
e
s
u
v
u
r
(
l
i
d
i
/
d
l
i
d
i
1
)
t
t
<
c
o
n
s
o
a
o
n
e
c
o
n
s
o
a
o
n
y
r		 0 1
1
-
T
l
E
B
I
T
t
o
a		 2
3
5		 2
0
5		 %
1
5
M
i
a
r
g
n		 9
3
%		 8
5
%

1 Prior year EBIT split adjusted to current portfolio

Fresenius Helios: 2010 Restructuring Plan

Y
i
f
l
i
t
e
a
r
s
n
p
o
r
o
o
1
<		 1 2 3 4 5 5
>		 l
T
t
o
a
f
l
N
i
i
o.
o
c
n
c
s
(
€
)
R
e
v
e
n
u
e
m		 -
-		 -
-		 6
1
8
6		 4
2
6
1		 7
1
7
5		 -
-		 2
5
1,
6
0
7		 4
2
2,
2
2
9
T
t
a
r
g
e
E
B
I
T
D
A
i
(
%
)
m
a
r
g
n
(
€
)
E
B
I
T
D
A
m		 -
-		 3.
0
-		 6.
0
2
1
1.		 9
0
2
3.
5		 1
2.
0
2
0.
9		 1
5.
0
-		 1
5.
0
2
4
1.
1		 2
9
6.
7
R
d
t
e
p
o
r
e
i
(
%
)
E
B
I
T
D
A
m
a
r
g
n
(
€
)
E
B
I
T
D
A
m		 -
-		 -
-		 0
4
7.
5		 1
0.
8
2
8.
2		 1
1.
9
2
0.
8		 -
-		 1
8
5.
2
2
5
4		 1
3.
9
3
0.
1
7
f
l
i
i
N
t
t
>
o.
o
c
n
c
s
a
r
g
e
f
l
i
i
N
t
t
<
o.
o
c
n
c
s
a
r
g
e		 -
-		 -
-		 3
3		 3
1		 4
3		 -
-		 1
4
1
1		 2
4
8
1

Fresenius Vamed: Sales and EBIT Growth Exceeding Guidance

€
m		 2
0
1
0		 2
0
0
9		 G
h
t
r
o
w
b
P
j
i
t
r
o
e
c
u
s
n
e
s
s
b
S
i
i
e
c
e
s
n
e
s
s
r
v
u		 8
4
7
2
2
6		 2
0
4
1
9
8		 6
%
1
1
4
%
l
l
T
t
o
a
s
a
e
s		 7
1
3		 8
6
1		 %
1
5
T
l
E
B
I
T
t
o
a
M
i
a
r
g
n		 4
1
5
8
%		 3
6
5
8
%		 1
4
%
1
O
d
i
k
t
r
e
r
n
a
e
1
O
d
b
k
l
r
e
r
a
c
o
g		 6
2
5
8
0
1		 5
3
9
6
7
9		 1
6
%
1
8
%

1Project business only

Cash Flow Development

€
m		 O
p
e
r
a		 C
i
F
t
n
g		 C
a
p
e		 (
)
t
x
n
e		 1
C
F
h
F
l
r
e
e
a
s
o
w
/
Q
4
1
0		 F
Y
M
i
a
r
g
n		 /
Q
4
1
0		 F
Y
M
i
a
r
g
n		 /
Q
4
1
0		 F
Y
M
i
a
r
g
n
1
8
9		 1
%
5
4		 (
)
6
0		 (
)
%
4
5		 1
2
9		 1
0
9
%
8
6		 1
2
3
%		 (
)
5
0		 (
)
6
4
%		 3
6		 3
6
0
%
0
4		 6
6
%		 (
2
)		 (
3
%
)
1		 3
8		 3
%
5
Co
/
te
rp
or
a
O
he
t
r		 1
-		 /
n
a		 (
)
5		 /
n
a		 6
-		 /
n
a
l.
F
M
C
ex
c		 3
1
4		 2
%
1
3
6		 (
)
1
1
7		 (
)
%
5
1		 1
9
7		 2
%
8
6
Gr
ou
p		 5
6
5		 2
0
%
1		 (
)
2
2
4		 (
)
%
4
6		 3
2
3		 %
7
4

1 Before Acquisitions and Dividends

2 Incl. FMC dividend

3 Understated: 8.7% excluding €70 million of Capex commitments from acquisitions

Margin = in % of sales

Fresenius Group: Debt and Interest Ratios

Debt excludes Mandatory Exchangeable Bonds

Fresenius Group: MEB and CVR Maturities

d
M
t
a
n
a
o
r
y
E
h
b
l
x
c
a
n
g
e
a
e
(
)
d
B
M
E
B
o
n		 1
2
0
1
1
M
t
A
t
4
a
e
s
g
s
u
r
u
u
-
,
f
d
b
€
2
0
R
i
i
1
1
i
1
1
t
t
t
e
o
n
o
n
e
e
s
e
p
e
n
s
e
m
n
u
c
r
x
y
~
-
1
'
k
C
d
b
3
0
%
F
i
i
F
M
5
t
t
t
t
e
e
n
e
n
e
p
e
e
o
e
r
s
u
s
s
a
x
c
a
~
-
C
i
t
t
o
n
n
g
e
n
l
i
h
V
R
t
a
e
g
u
(
)
C
V
R		 2
l
d
d
f
2
0
0
8
2
0
1
0
i
A
j
E
B
I
T
D
A
t
t
c
m
a
e
s
e
o
u
u
v
u
-
–
\$
b
l
\$
h
h
l
d
S
1
1
2
6
S
1
2
6
8
U
U
t
m
e
o
m
e
s
o
w
r
,
,
C
l
l
h
l
V
R
i
i
i
t
t
s
e
p
e
o
a
e
w
x
r
w
u
v
u
-
l
d
f
h
2
0
D
i
i
M
1
1
t
t
e
s
n
g
e
x
p
e
c
e
o
r
a
r
c
-

1 Based on current calculation

2 Pursuant to the agreement governing the CVRs

Fresenius Group: Financial Outlook

G
d
i
2
0
1
1
u
a
n
c
e		 C
G
/
A
R
2
0
1
0
1
1		 d
M
i
O
l
k
t
t
e
r
m
u
o
o
F
i
r
e
s
e
n
s
u
b
i
K
a		 S
l
h
t
a
e
s
g
r
o
w
E
B
I
T
i
m
a
g
n
r		 %
5
i
o
r
g
a
n
c
~
1
9
0
%
>		 8
9
%
i
o
r
g
a
n
c
–		 0
%
7
1
i
o
r
g
a
n
c
–
1
8
2
0
%
–
i
F
r
e
s
e
n
u
s
H
l
i
e
o
s		 l
h
S
t
a
e
s
g
r
o
w
E
B
I
T		 3
5
%
i
o
r
g
a
n
c
–
€
2
0
2
6
0
5
m
–		 4
5
%
i
o
r
g
a
n
c
–		 l
S
a
e
s
€
3
b
b
2
0
5
1
5
n
y
i
F
r
e
s
e
n
u
s
V
d
a
m
e		 l
h
S
t
a
e
s
g
o
r
w
h
E
B
I
T
t
g
r
o
w		 5
1
0
%
–
0
%
5
1
–		 1
0
%
>		 l
S
a
e
s
€
b
b
2
0
1
1
4
n
y
F
i
r
e
s
e
n
u
s
B
i
h
t
o
e
c		 E
B
I
T		 €
3
0
m
~
-

Fresenius Group: Financial Outlook

G
i
d
2
0
1
1
u
a
n
c
e		 C
G
/
A
R
2
0
1
0
1
1		 M
i
d
O
l
k
t
t
e
r
m
u
o
o
h
R
t
e
v
e
n
u
e
g
r
o
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 7
%
≥		 8
%
7
–
1
h
i
N
t
t
e
n
c
o
m
e
g
o
r
w
t
t
t
a
c
o
n
s
a
n
c
e
n
c
u
r
r
y		 8
2
%
1
–		 %
1
5
1
7
–		 h
l
S
t
t
e
c
g
o
a
r
:
€
b
b
2
0
1
1
4
>
n
y
C
a
p
e
x		 f
%
5
o
~
G
l
o
p
s
a
e
s
r
u

1 Net income attributable to Fresenius SE & Co. KGaA and before special items due to MEB and CVR accounting

Attachments

Special items

    • Other financial result:
    • CVR (Contingent Value Right): The trading price of the CVR on the B/S date is considered as fair redemption value. Changes of this value are recognized in the P&L. Valuation changes will lead to quarterly gains or expenses until maturity.

Calculation as of December 31, 2010: Δ between trading price of US\$0.30 at December 31, 2009 and trading price at December 31, 2010 of US\$0.04 multiplied by 163.3 million CVRs = US\$42.3 million = €32 million.

  • MEB (Mandatory Exchangeable Bond): Mark-to-market accounting based on the Black-Scholes valuation model reflecting FMC's share price. Any change in fair value is recognized in the P&L. Valuation changes will lead to gains or expenses until maturity.

Fresenius Group:

Overview – Calculation of Noncontrolling Interest

€
m		 2
0
0
1		 2
0
0
9
b
f
d
l
l
E
i
i
i
t
t
t
t
a
r
n
n
g
s
e
o
r
e
a
x
a
n
n
o
n
c
o
n
r
o
n
g
n
e
r
e
s		 1
7
8
6
,		 1
4
4
3
,
T
e
a
x
s		 8
5
1
-		 2
4
5
-
l
l
h
f
i
i
N
t
t
t,
t
o
n
c
o
n
o
n
g
n
e
e
s
e
e
o
r
r
r		 8
3
5
-		 9
4
7
-
i
d
i
l
C
i
F
M
t
t
r
e
s
e
n
u
s
e
c
a
a
r
e
n
e
n
c
o
m
e
n
o
b
b
l
(
)
i
F
i
6
5
%
t
t
t
t
a
r
u
a
e
o
r
e
s
e
n
u
s
~		 6
4
7
-		 4
1
1
-
l
l
h
l
d
d
l
C
N
i
i
i
F
i
M
i
t
t
t
o
n
c
o
n
r
o
n
g
n
e
r
e
s
o
e
r
s
n
r
e
s
e
n
u
s
e
c
a
a
r
e
(
/
\$
/
\$
d
F
Y
2
0
0
9
U
S
7
4
F
Y
2
0
1
0
U
S
8
7
i
m
m
a
c
c
o
n
g
:
:
r
,
d
l
's
l
)
F
i
M
i
C
F
i
i
S
t
t
t
t
o
e
s
e
n
s
e
c
a
a
e
n
a
n
c
a
a
e
m
e
n
s
r
u
r		 6
6
-		 3
5
-
l
l
h
l
d
b
N
i
i
i
F
i
K
i
t
t
t
o
n
c
o
n
o
n
g
n
e
e
s
o
e
s
n
e
s
e
n
s
a
r
r
r
r
u
(
€
2
2
),
l
(
€
2
)
d
d
F
i
H
i
1
t
m
r
e
s
e
n
u
s
e
o
s
m
a
n
u
e
o
-
-
d
's
l
h
(
)
F
i
V
2
3
%
i
€
7
t
r
e
s
e
n
u
s
a
m
e
e
x
e
r
n
a
o
w
n
e
r
s
p
m
-		 4
1
-		 3
3
-
b
b
l
S
&
C
G
N
i
i
F
i
E
K
A
t
t
t
t
t
e
n
c
o
m
e
a
a
e
o
e
s
e
n
s
o
a
r
u
r
u		 6
2
2		 9
4
4

Fresenius Group: Cash Flow

€
m		 2
0
1
0		 L
T
M
M
i
a
r
g
n		 2
0
0
9		 L
T
M
M
i
a
r
g
n		 G
h
t
r
o
w
Y
Y
o
O
i
C
h
F
l
t
p
e
r
a
n
g
a
s
o
w		 1
9
1
1
,		 1
2
0
%		 1
5
5
3
,		 1
1
0
%		 2
3
%
C
(
)
t
a
p
e
x
n
e		 7
3
3
-		 4
6
%		 6
6
2
-		 4
7
%		 1
1
%
-
C
h
l
F
F
r
e
e
a
s
o
w
(
b
f
d
d
d
d
)
i
i
t
i
i
i
e
o
e
a
c
q
s
o
n
s
a
n
e
n
s
r
u
v		 1
1
7
8
,		 %
7
4		 8
9
1		 %
6
3		 %
3
2
(
)
A
i
i
t
i
t
c
q
s
o
n
s
n
e
u		 0
5
4
-		 2
2
7
-		 2
2
%
1
-
d
d
D
i
i
v
e
n
s		 3
2
9
-		 2
7
5
-		 2
0
%
-
C
F
h
F
l
r
e
e
a
s
o
w
(
f
d
d
d
d
)
i
i
i
i
i
t
t
a
e
r
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 3
4
5		 2
2
%		 3
8
9		 2
7
%		 1
1
%
-

Cash Flow Development LTM

€
m		 O
p
e
r
a		 (
)
C
C
C
i
F
F
h
F
l
t
t
n
g
a
p
e
x
n
e
r
e
e
a
s
o		 1
w
2
0
1
0		 M
i
a
r
g
n		 2
0
1
0		 M
i
a
r
g
n		 2
0
1
0		 M
i
a
r
g
n
6
5
7		 1
%
5
4		 (
)
1
6
6		 (
)
%
4
5		 0
1
4		 1
0
9
%
3
1
1		 1
2
3
%		 (
)
1
6
1		 (
)
6
4
%		 1
5
0		 3
6
0
%
4
7		 6
6
%		 (
9
)		 (
3
%
)
1		 3
8		 3
%
5
Co
/
te
rp
or
a
O
he
t
r		 4
6
-		 /
n
a		 (
)
1
4		 /
n
a		 6
0
-		 /
n
a
l.
F
M
C
ex
c		 8
7
9		 2
%
1
3
6		 (
)
3
5
0		 (
)
%
5
1		 5
2
9		 2
%
8
6
Gr
ou
p		 9
1
1
1
,		 2
0
1		 (
)
3
3
7		 (
)
%
4
6		 8
1
1
7
,		 %
7
4

1 Before Acquisitions and Dividends

2 Incl. FMC dividend

3 Understated: 8.7% excluding €70 million of Capex commitments from acquisitions

Margin = in % of sales

Fresenius Group: Solid Balance Sheet Structure

Fresenius Group: Debt Maturity Profile 1December 31, 2010

1Based on utilization of major financing instruments; excl. Fresenius Medical Care's accounts receivable facility

Fresenius Kabi: Strong Organic Sales Growth

€
m		 2
0
1
0		 2
0
0
9		 O
i
r
g
a
n
c
G
h
t
r
o
w
f
h
I
i
T
n
u
s
o
n
e
r
a
p
y		 8
3
4		 2
7
1		 6
%
I
V
D
r
u
g
s		 3
2
8
1
,		 0
2
1
7
,		 2
3
%
C
l
l
i
i
N
i
i
t
t
n
o
n
c
a
u
r		 0
6
2
1
,		 9
2
4		 9
%
d
i
l
i
/
M
D
e
c
a
e
c
e
s
v
f
h
l
T
i
T
r
a
n
s
u
s
o
n
e
c
n
o
o
g
y		 3
9
4		 2
3
4		 %
1
T
l
l
t
o
a
s
a
e
s		 3
6
2
7
,		 3
0
8
6
,		 1
2
%

Fresenius Kabi: Strong Organic Sales Growth

€
m		 2
0
1
0		 2
9
0
0		 O
i
r
g
a
n
c
G
h
t
r
o
w
E
o
p
e
u
r		 0
2
1
7
,		 6
6
1
5
,		 6
%
h
N
A
i
t
o
r
m
e
r
c
a		 9
7
5		 2
8
7		 2
6
%
f
A
i
P
i
i
s
a
a
c
c
-		 5
9
3		 4
8
2		 1
3
%
f
/
L
i
A
i
A
i
t
a
n
m
e
c
a
c
a
r
r		 0
2
4		 3
0
1		 0
%
1
T
l
l
t
o
a
s
a
e
s		 3
6
7
2
,		 3
0
8
6
,		 1
2
%

Fresenius Kabi: Profit and Loss Statement

€
m		 2
0
1
0		 2
0
0
9		 R
k
2
0
1
0
e
m
a
r
s
l
S
a
e
s
f
d
l
d
C
t
o
s
o
g
o
o
s
s
o
G
f
i
t
o
p
o
r
s
s
r
f
l
%
o
s
a
e
s		 3
6
7
2
,
1
9
6
1
-
,
1
7
1
1
,
4
6
6		 3
0
8
6
,
1
6
4
2
-
,
1
4
4
4
,
4
6.
8		 1
2
%
i
h
t
o
r
g
a
n
c
g
r
o
w
S
G
&
A
f
l
%
o
s
a
e
s		 8
3
1
-
2
2
6		 0
8
7
-
2
2.
9
&
R
D
e
p
e
n
s
e
s
x
f
l
%
o
s
a
e
s		 3
1
4
-
3
9		 2
9
1
-
4
2
E
B
I
T
D
A		 8
9
3		 2
7
4
i
%
m
a
r
g
n		 2
4
3		 2
0
4

Fresenius Kabi: Profit and Loss Statement (cont'd)

€
m		 2
0
1
0		 2
0
0
9		 k
R
2
0
1
0
e
m
a
r
s
E
B
I
T
i
%
m
a
g
n
r		 7
3
7
2
0
1		 6
0
7
1
9
7
N
i
t
t
t
e
n
e
r
e
s		 2
7
9
-		 3
0
2
-
b
f
E
i
t
a
r
n
n
g
s
e
o
r
e
a
x
e
s
d
l
l
i
t
a
n
n
o
n
c
o
n
o
n
g
r
i
t
t
n
e
r
e
s		 4
5
8		 3
0
5
I
t
n
c
o
m
e
a
e
s
x
T
%
t
a
a
e
x
r		 1
4
2
-
3
1.
0		 8
9
-
2
9
2		 b
D
i
U
S
i
r
v
e
n
y
e
a
r
n
n
g
s
l
l
N
i
i
t
t
t
o
n
c
o
n
r
o
n
g
n
e
r
e
s		 2
2
-		 1
6
-		 b
i
i
i
t
t
c
o
n
o
n
c
a
n
g
a
r
u
r
r
y
h
i
h
t
t
g
e
r
a
x
r
a
e
1
N
i
t
e
n
c
o
m
e		 2
9
4		 2
0
0

Attributable to Fresenius Kabi AG

Fresenius Kabi: Cash Flow Statement

€
m		 2
0
0
1		 2
0
0
9		 k
R
2
0
1
0
e
m
a
r
s
N
i
t
e
n
c
o
m
e
(
l.
l
l
)
i
i
i
t
t
t
n
c
n
o
n
c
o
n
r
o
n
g
n
e
r
e
s		 3
1
6		 2
6
1
/
D
i
i
i
i
t
t
t
e
p
r
e
c
a
o
n
a
m
o
r
z
a
o
n		 1
5
6		 1
3
5
h
k
l
C
i
i
i
t
a
n
g
e
n
o
n
g
c
a
p
a
w
r		 9
5		 4
6
h
f
l
f
C
i
t
a
s
o
w
r
o
m
o
p
e
r
a
o
n
s
M
i		 5
6
7		 3
9
7
1
2.
9
%
a
r
g
n		 1
5
4
C
A
P
E
X
t
n
e
,		 1
6
6
-		 1
2
5
-		 d
7
2
%
i
i
t
e
o
n
s
c
r
a
r
y,
h
f
l
C
a
s
o
w		 0
4
1		 2
2
7		 2
8
%
d
i
i
t
n
o
n-
s
c
r
e
o
n
a
r
y
b
f
d
d
d
d
i
i
i
i
i
t
e
o
e
a
c
q
s
o
n
s
a
n
e
n
s
r
u
v
A
i
i
i
t
t
c
q
u
s
o
n
s
n
e
,		 1
9
-		 2
6
-
h
f
l
F
(
b
f
d
d
d
)
r
e
e
c
a
s
o
w
i
i
e
o
r
e
v
e
n
s		 3
8
2		 2
4
6

Fresenius Kabi: Balance Sheet

€
m		 2
0
1
0		 2
0
0
9		 R
k
2
0
1
0
e
m
a
r
s
b
l
A
i
t
c
c
o
u
n
s
r
e
c
e
v
a
e		 6
8
1		 6
1
2		 D
S
O
2
0
1
0
6
9
d
(
2
0
0
9
7
3
)
:
a
y
s
:
I
i
t
n
e
n
o
e
v
r
s		 6
6
0		 6
0
5		 d
(
)
S
O
I
2
0
1
0
1
4
2
2
0
0
9
1
4
1
a
s
:
y
:
d
F
i
t
x
e
a
s
s
e
s		 4
9
7
2
,		 4
6
3
3
,		 G
d
i
l
l
(
D
3
1,
2
0
1
0
)
€
3,
7
0
7
o
o
w
e
c
:
m
O
h
t
t
e
a
s
s
e
s
r		 5
4
7		 3
0
5
T
l
t
t
o
a
a
s
s
e
s		 6
8
6
0
,		 6
3
3
5
,
b
D
t
e		 4
2
9
8
,		 4
1
8
4
,
O
h
l
i
b
i
l
i
i
t
t
e
a
e
s
r		 2
0
1
1
,		 0
0
0
1
,
E
i
t
(
l.
l
l
)
q
u
y
i
i
i
t
t.
n
c
n
o
n
c
o
n
r
o
n
g
n		 1
3
6
1
,		 1
1
5
1
,
T
l
l
i
b
i
l
i
i
d
t
t
o
a
a
e
s
a
n
h
h
l
d
'
i
t
s
a
r
e
o
e
r
s
e
q
u
y		 8
6
6
0
,		 3
3
6
5
,

Fresenius Helios: Strong Organic Sales Growth

€
m		 2
0
0
1		 2
0
0
9		 G
h
t
r
o
w
b
l
h
d
l
f
l
E
i
i
i
i
t
t
s
a
s
e
c
n
c
p
o
r
o
o		 2
2
0
5
,		 1
2
0
4
5
,		 %
5
A
i
i
i
t
c
q
s
o
n
s
(
l
i
d
i
)
u
t
1
<
c
o
n
s
o
a
o
n
y
r
D
i
i
t
t
v
e
s
u
r
e
s
(
d
l
i
d
i
1
)
t
<
e
c
o
n
s
o
a
o
n
y
r		 0 1
1
1
T
l
l
t
o
a
s
a
e
s		 2
5
2
0
,		 2
4
1
6
,		 4
%

1Prior year sales split adjusted to current portfolio

Fresenius Helios: Performance Indicators

2
0
1
0		 2
0
0
9		 C
h
a
n
g
e
f
h
l
N
i
t
o
o
o
s
p
a
s
l
A
i
i
t
c
u
e
c
n
c
s
-
1
P
l
i
i
t-
t
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 6
2
4
2
2
0		 6
2
4
3
1
9		 0
%
-2
%
5
%
f
b
d
N
o
o
e
s
l
A
i
i
t
c
u
e
c
n
c
s
-
l
P
i
i
t-
t
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 1
8
5
6
4
,
1
5,
0
9
7
3,
4
6
7		 1
8
5
8
3
,
1
5,
1
1
6
3,
4
6
7		 0
%
0
%
0
%
2
d
A
i
i
m
s
s
o
n
s
(
)
A
i
i
t
t
t
e
a
e
n
p
a
e
n
c
u
c
r
-		 6
0
6,
8
8
0		 5
8
6,
1
2
3		 4
%
2
O
c
c
u
p
a
n
c
y
P
t-
t
o
s
a
c
e
c
a
e
u
r
-		 8
0
%		 8
3
%
2
l
h
f
(
d
)
A
t
t
v
e
r
a
g
e
e
n
g
o
s
a
y
a
y
s
A
t
c
e
c
a
e
u
r
-
P
t-
t
o
s
a
c
e
c
a
e
u
r
-		 6.
9
2
9
5		 7.
1
2
9
7
d
d
b
%
f
l
B
i
t
a
e
n
o
s
a
e
s		 0
2
%		 0
2
%

1Reporting change: one additional post-acute care clinic formerly shown as part of an acute clinic. 2 Clinics in Germany

Fresenius Helios: Sales Influence Hospital Acquisitions

i
i
i
A
t
c
q
s
o
n
s
u		 l
i
d
l
A
n
n
a
e
s
a
e
s
u
z
n
o
n
e
D
i
i
t
t
v
e
s
u
r
e
s
l
d
i
H
t
D
o
s
p
a
e
s
e
n
r		 €
1
1
m
~		 d
l
d
d
f
i
1
2
0
1
0
t
J
e
c
o
n
s
o
a
e
a
s
o
a
n
,
i
i
i
A
2
0
1
1
t
c
q
s
o
n
s
u
l
l
d
H
i
H
t
t
t
o
s
p
a
e
m
s
e		 €
3
2
m
~		 l
d
d
f
i
J
1
2
0
1
1
t
c
o
n
s
o
a
e
a
s
o
a
n
,

Fresenius Helios: Profit & Loss Statement

€
m		 2
0
1
0		 2
0
0
9		 k
R
2
0
1
0
e
m
a
r
s
l
S
a
e
s		 2
2
0
5
,		 2
6
4
1
,
O
i
t
p
e
n
g
e
p
e
n
e
r
a
x
s
s
:
f
S
l
i
d
b
i
t
a
a
r
e
s,
w
a
g
e
s
a
n
e
n
e
s		 1
4
9
0
-
,		 6
1,
4
4
-
l
S
i
p
p
e
s
u		 4
9
1
-		 9
4
4
-
h
O
t
e
s
r		 2
2
1
-		 9
0
1
-
E
B
I
T
D
A
M
i
%
a
g
n
r		 3
1
8
1
2
6		 2
8
6
1
1.
8
/
D
i
i
i
i
t
t
t
e
p
r
e
c
a
o
n
a
m
o
r
z
a
o
n		 8
3
-		 8
1
-
E
B
I
T
%
M
i
a
r
g
n		 2
3
5
9
3		 2
0
5
8.
5

Fresenius Helios: Profit & Loss Statement (cont'd)

€
m		 2
0
0
1		 2
0
0
9		 R
k
2
0
1
0
e
m
a
r
s
N
i
t
t
t
e
n
e
r
e
s		 5
5
-		 5
5
-
b
f
d
E
i
t
a
r
n
n
g
s
e
o
r
e
a
x
e
s
a
n
l
l
i
i
t
t
t
n
o
n
c
o
n
o
n
g
n
e
e
s
r
r		 1
8
0		 0
1
5
I
t
n
c
o
m
e
a
x
e
s
%
T
t
a
x
r
a
e		 3
7
-
2
0
6		 3
2
-
2
3
1.
l
l
N
i
i
t
t
t
o
n
c
o
n
r
o
n
g
n
e
r
e
s		 1
2
-		 1
1
-
1
N
i
t
e
n
c
o
m
e		 1
3
1		 0
1
7

Attributable to Helios Kliniken GmbH

Fresenius Helios: Cash Flow

€
m		 2
0
1
0		 2
0
0
9		 R
k
2
0
1
0
e
m
a
r
s
N
i
t
e
n
c
o
m
e
(
l.
l
l
)
i
i
i
t
t
t
n
c
n
o
n
c
o
n
o
n
g
n
e
e
s
r
r		 3
1
4		 8
1
1
/
D
i
i
i
i
t
t
t
e
p
e
c
a
o
n
a
m
o
a
o
n
r
r
z		 8
3		 8
1
C
h
k
l
i
i
i
t
a
n
g
e
n
o
n
g
c
a
p
a
w
r		 8
5		 2
0
f
f
C
h
l
i
t
a
s
o
o
m
o
p
e
a
o
n
s
w
r
r
M
i
%
a
r
g
n		 3
1
1
1
2
3		 2
9
1
9
1
C
A
P
E
X
t
n
e
,		 1
6
1
-		 1
2
4
-
h
f
l
C
a
s
o
w
b
f
d
d
d
d
i
i
t
i
i
i
e
o
r
e
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 1
5
0		 9
5
i
i
i
A
t
t
c
q
s
o
n
s
n
e
u
,		 3
1
-		 6
2
-
h
f
l
F
e
e
c
a
s
o
(
b
f
d
d
d
)
r
w
i
i
e
o
r
e
v
e
n
s		 3
1
7		 3
3

Fresenius Helios: Balance Sheet

€
m		 2
0
1
0		 2
0
0
9		 k
R
2
0
1
0
e
m
a
r
s
b
l
A
i
t
c
c
o
u
n
s
r
e
c
e
v
a
e		 2
6
1		 2
3
9		 d
(
)
D
S
O
2
0
1
0
3
8
2
0
0
9
3
6
a
s
:
y
:
l
d
(
)
P
i
t
t
t
t
r
o
p
e
r
y
p
a
n
a
n
e
q
u
p
m
e
n
n
e
,		 0
8
8
1
,		 0
0
0
1,
d
l
l
G
i
o
o
w		 1
5
9
9
,		 1,
5
9
8		 l.
d
l
l
f
h
I
i
H
E
L
I
O
S
t
n
c
g
o
o
w
r
o
m
e
(
)
i
i
i
i
2
0
0
5
€
1,
1
6
6
t
a
c
q
s
o
n
n
m
u
h
O
t
t
e
a
s
s
e
s
r		 3
2
2		 3
6
2
l
T
t
t
o
a
a
s
s
e
s		 3
2
7
0
,		 3
1
9
9
,
b
D
t
e		 1
0
9
6
,		 0
9
9
1,		 l.
d
b
f
O
S
i
i
i
I
t
H
E
L
I
t
n
c
e
r
o
m
a
c
q
u
s
o
n
i
2
0
0
(
€
6
0
0
)
5
n
m
O
h
l
b
l
t
i
i
i
t
i
e
r
a
e
s		 3
7
7		 7
7
1
E
i
t
(
i
l.
l
l
i
i
)
t
t
t
q
u
y
n
c
n
o
n
c
o
n
r
o
n
g
n
e
r
e
s		 1
4
0
1
,		 1,
3
2
9		 E
i
i
4
2.
8
%
t
t
q
a
o
u
y
r
:
l
l
i
b
i
l
i
i
d
T
t
t
o
a
a
e
s
a
n
h
h
l
d
i
'
t
s
a
r
e
o
e
r
s
e
q
u
y		 3
2
7
0
,		 3
1
9
9
,

Fresenius Vamed: Sustainable EBIT Development

€
m		 2
0
1
0		 2
0
0
9		 C
h
a
n
g
e
b
P
j
i
t
o
e
c
s
n
e
s
s
r
u
M
i
a
r
g
n		 2
3
4
7
%		 8
1
4
3
%		 2
8
%
S
b
i
i
e
e
n
e
r
v
c
u
s
s
s
M
i
a
r
g
n		 1
8
8.
0
%		 1
8
9
1
%		 0
%
T
l
E
B
I
T
t
o
a		 4
1		 3
6		 %
1
4
M
i
a
r
g
n		 %
5
8		 %
5
8
1
N
i
t
e
n
c
o
m
e		 3
0		 2
7		 1
1
%

Attributable to Vamed AG

Fresenius Vamed: Profit & Loss Statement

€
m		 2
0
1
0		 2
0
0
9		 R
k
2
0
1
0
e
m
a
r
s
l
S
a
e
s		 1
3
7		 6
1
8		 O
h
%
i
t
1
5
r
g
a
n
c
g
r
o
w
:
f
d
l
d
C
t
o
s
o
g
o
o
s
s
o		 6
0
4
-		 5
2
3
-
f
G
i
t
o
s
s
p
o
r
r
M
i
%
a
g
n
r		 1
0
9
1
5
3		 9
5
1
5.
4
S
G
&
A
%
f
l
o
s
a
e
s		 6
8
-
9
5		 9
5
-
9
5
E
B
I
T
D
A
M
i
%
a
g
n
r		 4
9
6
9		 4
2
6.
8
E
B
I
T
M
i
%
a
r
g
n		 4
1
5
8		 3
6
5.
8

Fresenius Vamed: Profit & Loss Statement (cont'd)

€
m		 2
0
1
0		 2
0
0
9		 R
k
2
0
1
0
e
m
a
r
s
N
i
t
t
t
e
n
e
e
s
r		 2 3 d
I
i
t
t
t
t
n
e
e
s
n
c
o
m
e
e
o
p
e
p
a
m
e
n
s
r
u
r
y
f
b
E
i
t
a
n
n
g
s
e
o
e
a
e
s
r
r
x
d
l
l
i
t
a
n
n
o
n
c
o
n
r
o
n
g
i
t
t
n
e
e
s
r		 3
4		 3
9
I
t
n
c
o
m
e
a
e
s
x
T
%
t
e
a
x
r
a		 2
1
-
2
8
3		 1
2
-
2
9
9
l
l
N
i
i
t
t
t
o
n
c
o
n
r
o
n
g
n
e
r
e
s		 1
-		 0
1
N
i
t
e
n
c
o
m
e		 3
0		 2
7
(
b
f
)
R
O
E
%
t
e
o
e
a
e
s
r
x		 2
1
9		 2
2
0

Attributable to Vamed AG

Fresenius Vamed: Cash Flow

€
m		 2
0
1
0		 2
0
0
9		 R
k
2
0
1
0
e
m
a
r
s
N
i
t
e
n
c
o
m
e
(
l.
l
l
)
i
i
i
t
t
t
n
c
n
o
n
c
o
n
o
n
g
n
e
e
s
r
r		 3
1		 2
7
/
D
i
i
i
i
t
t
t
e
p
e
c
a
o
n
a
m
o
a
o
n
r
r
z		 8 6
C
h
k
l
i
i
i
t
a
n
g
e
n
o
n
g
c
a
p
a
w
r		 8 4
-
f
f
C
h
l
i
t
a
s
o
o
m
o
p
e
a
o
n
s
w
r
r
M
i
%
a
r
g
n		 4
7
6
6		 2
9
4
7
C
A
P
E
X
t
n
e
,		 9
-		 5
-
h
f
l
C
a
s
o
w
b
f
d
d
d
d
i
i
t
i
i
i
e
o
r
e
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 3
8		 2
4
i
i
i
A
t
t
c
q
s
o
n
s
n
e
u
,		 4
-		 1
-
h
f
l
F
e
e
c
a
s
o
(
b
f
d
d
d
)
r
w
i
i
e
o
r
e
v
e
n
s		 3
4		 2
3

Fresenius Vamed: Balance Sheet

€
m		 2
0
1
0		 2
0
0
9		 R
k
2
0
1
0
e
m
a
r
s
b
l
A
i
t
c
c
o
n
s
e
c
e
a
e
u
r
v		 8
5		 7
8		 d
(
)
D
S
O
2
0
1
0
4
1
2
0
0
9
4
4
:
a
y
s
:
l
d
P
i
t
t
t
r
o
p
e
r
y
p
a
n
a
n
e
q
u
p
m
e
n
,		 2
6		 2
6
b
l
I
t
i
t
n
a
n
g
e
a
s
s
e
s		 3
5		 8
4
O
h
t
t
e
e
r
a
s
s
s		 3
8
5		 3
0
4		 C
h
&
C
h
i
l
t
a
s
a
s
e
q
u
v
a
e
n
s
T
l
t
t
o
a
a
s
s
e
s		 5
4
9		 4
5
6		 (
3
2
0
0
)
€
9
D
1,
1
7
e
c
:
m
b
D
t
e		 1
6		 2
O
h
l
b
l
i
i
i
i
t
t
e
r
a
e
s		 3
3
7		 2
7
7
E
i
t
(
l.
l
l
)
i
t
i
i
t
t
q
u
y
n
c
n
o
n
c
o
n
r
o
n
g
n
e
r
e
s		 9
1
6		 1
7
7		 (
)
E
i
R
i
D
3
1,
2
0
1
0
3
5.
7
%
t
t
q
a
o
e
c
u
y
:
T
l
l
i
b
i
l
i
i
d
t
t
o
a
a
e
s
a
n
h
h
l
d
i
t
'
s
a
r
e
o
e
r
s
e
q
u
y		 5
4
9		 4
5
6

Fresenius Group: Key Figures According to IFRS

€
m		 2
0
1
0
U
S
G
A
A
P		 2
0
1
0
I
F
R
S
S
l
a
e
s		 9
2
1
5
7
,		 1
5
9
7
2
,
E
B
I
T		 2
1
8
4
,		 2
0
4
1
,
N
i
t
t
t
e
n
e
r
e
s		 5
6
6
-		 5
6
6
-
1
N
i
t
e
n
o
m
e
c		 6
2
2		 9
6
1
2
N
i
t
e
n
c
o
m
e		 6
6
0		 6
5
7
h
f
l
O
i
C
t
p
e
r
a
n
g
a
s
o
w		 1
9
1
1
,		 1
9
2
1
,
l
h
l
B
t
t
t
a
a
n
c
e
s
e
e
o
a		 2
3
5
7
7
,		 2
3
8
3
1
,

1Net income attributable to Fresenius SE & Co. KGaA

2Net income attributable to Fresenius SE & Co. KGaA before special items due to MEB and CVR accounting

Financial Calendar

  • 04.05.2011 Report on 1st quarter 2011
  • 13.05.2011 Annual General Meeting, Frankfurt/Main
  • 02.08.2011 Report on 1st half 2011
  • 02.11.2011 Report on 1st 3rd quarter 2011

Contact

Birgit Grund SVP Investor Relations Fresenius SE & Co. KGaA Telephone: +49 6172 608-2485 e-mail: [email protected]

For further information and current news: http://www.fresenius.com

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.